Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia

NCT00254163 is registered in ClinicalTrials.gov with US Oncology Research as lead sponsor.

NCT NCT00254163
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00254163 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Open Label, Phase III Trial of Fludarabine, Cyclophosphamide, and Rituximab vs. Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-cell Chronic Lymphocytic Leukemia
Lead sponsor
US Oncology Research
Phase
Phase 3
Overall status
Completed
Start date
December 31, 2003
Completion date
September 30, 2011
Enrollment
184 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell chronic lymphocytic leukemia